Lead Programs
NKX101
Engineered to target NKG2D ligands
- Opportunity to treat a variety of hematologic malignancies and solid tumors
- Targets of NKG2D are selectively over-expressed in cancer cells
- Native NK activation and tumor killing largely driven by NKG2D receptor
- For NKX101, expression of the activating chimeric receptor is increased 10X relative to nonengineered NK cells
- OX40 selected based on superiority vs. other costimulatory domains
- Visit ClinicalTrials.gov for more information on the
NKX101 Phase 1 clinical trial. Identifier: NCT04623944
NKX101: NKG2D activating receptor, OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound IL-15
NKX019
Engineered to target CD19
For patients with many B-cell malignancies, there remains a substantial unmet medical need today.
- Large opportunity remains despite approved autologous CAR-T products:
- Gr3+ cytokine release syndrome (CRS): 13-49%
- Gr3+ neurotoxicity: 18-31%
- Limited number of specialized sites can treat
- Compelling commercial opportunity
- A Phase 1 clinical trial of NKX019 is currently enrolling patients. Please visit ClinicalTrials.gov for more information. Identifier: NCT05020678
NKX019: Proprietary CD19 binder, OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound IL-15